| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2136820 | Leukemia Research | 2013 | 7 Pages |
Abstract
Thalidomide has a strong potential to improve response and survival measures in patients with standard risk MM. Combined regimens should be used, with lower doses of thalidomide. High risk myelomas should be treated individually.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jiri Minarik, Viera Sandecka, Vladimir Maisnar, Evzen Gregora, Ivan Spicka, David Starostka, Hana Plonkova, Jiri Jarkovsky, Lenka Walterova, Marek Wrobel, Dagmar Adamova, Tomas Pika, Hana Melicharova, Ludek Pour, Jakub Radocha, Petr Pavlicek, Jan Straub,